Form 4: Daniell Richard sold TEVA
Daniell Richard (EVP, Europe Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 45,003 shares of TEVA at an average $42.86, roughly $1,928,944, in a Form 4 filed 2026-11-12.
Past performance does not predict future results. Informational only, not investment advice.
Daniell Richard (EVP, Europe Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 45,003 shares of TEVA at an average $42.86, roughly $1,928,944, in a Form 4 filed 2026-11-12.
Sabag Mark (See "Remarks" at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 44,710 shares of TEVA at an average $44.14, roughly $1,973,544, in a Form 4 filed 2026-11-12.
Weiss Amir (Chief Accounting Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 17,289 shares of TEVA at an average $43.04, roughly $744,049, in a Form 4 filed 2026-11-12.
Sabag Mark (See "Remarks" at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 46,000 shares of TEVA at an average $41.93, roughly $1,928,729, in a Form 4 filed 2026-11-06.
Bergwerk Dov (Interim Cheif Legal Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD) reported an open-market sale of 26,260 shares of TEVA at an average $41.72, roughly $1,095,567, in a Form 4 filed 2026-11-06.
End of results.